Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVLO Stock Price Chart Interactive Chart >
EVLO Price/Volume Stats
| Current price | $2.16 | 52-week high | $9.34 |
| Prev. close | $2.21 | 52-week low | $1.42 |
| Day low | $2.05 | Volume | 53,700 |
| Day high | $2.20 | Avg. volume | 248,950 |
| 50-day MA | $2.07 | Dividend yield | N/A |
| 200-day MA | $2.40 | Market Cap | 233.27M |
Evelo Biosciences, Inc. (EVLO) Company Bio
Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Latest EVLO News From Around the Web
Below are the latest news stories about EVELO BIOSCIENCES INC that investors may wish to consider to help them evaluate EVLO as an investment opportunity.
Chardan Capital downgrades Evelo Biosciences (EVLO) to a HoldEvelo Biosciences (EVLO - Research Report) received a Hold rating and a $2.50 price target from Chardan Capital analyst Keay Nakae today. The company's shares closed yesterday at $2.19.According to TipRanks, Nakae is a 3-star analyst with an average return of 2.7% and a 38.36% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arbutus Biopharma, and Sonnet BioTherapeutics Holdings.Evelo Biosciences has an analyst consensus of Hold, with a price target consensus of $3.25.See the top stocks recommended by analysts >>The company has a one-year high of $10.57 and a one-year low of $1.42. Currently, Evelo Biosciences has an average volume of 141K. |
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in ImmunologyPeer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX medicines, today announced the publication of a peer-reviewed article explaining the scientific basis of the Small Intestinal Axis1 and that it will hold a Science Symposium on Wednesday, |
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle product candidate EDP2939 in psoriasis anticipated in 2H 2023 – - Continuing to advance regulatory discussions for registration trials for EDP1815 in psoriasis - CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology com |
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare ConferenceCAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced that Simba Gill, Ph.D., Chief Executive Officer of Evelo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 7:25 a.m. GMT. A live audio webcast of the presentation will be available he |
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) CongressCAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today presented biomarker data demonstrating the broad anti-inflammatory effects of EDP1815, the Company’s lead product candidate in inflammation, in a Phase 2 clinical trial in psoriasis. The data were presented in a poster at the 2022 EADV Congress in Milan, Ital |
EVLO Price Returns
| 1-mo | 1.41% |
| 3-mo | -10.37% |
| 6-mo | -5.26% |
| 1-year | -73.82% |
| 3-year | -51.35% |
| 5-year | N/A |
| YTD | -64.42% |
| 2021 | -49.79% |
| 2020 | 197.78% |
| 2019 | -68.79% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...